We therefore make the case that the role of P2RY12-inhibitors in cancer progression and cancer-associated-thrombosis warrants further investigation as a possible and new therapeutic target in pancreatic adenocarcinomas. The gene discussed is P2RY12; the disease is pancreatic adenocarcinoma.